Skip to main content
Signal8

Seer, Inc. (SEER)

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Sector: Laboratory Analytical Instruments

Industry: Biotechnology

Seer, Inc. logo

Seer, Inc.

NASDAQ:SEERHealthcare
-13.40%$1.68
AH$1.70+1.19%vs close
Mkt Cap$93.02M
Float32.53M
O/S55.37M
Vol
$ Vol
RVOL
Inst Own37.0%
SI0.3%
Earnings
Dilution
FormDescription
8-K
8.01,9.01
3
3
Initial Statement of Beneficial Ownership
8-K
4
Statement of Changes in Beneficial Ownership
10-Q
8-K
8-K
5.07
8-K
8.01,9.01
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
DFAN14A
SEC Filing
3
DFAN14A
SEC Filing
DEFA14A
Additional Proxy Materials
2
DFAN14A
SEC Filing
4
DEFA14A
Additional Proxy Materials
2
8-K
8.01,9.01
2
DEFA14A
Additional Proxy Materials
3
DEFA14A
Additional Proxy Materials
2
DFAN14A
SEC Filing
4
DEFA14A
Additional Proxy Materials
3
DEFA14A
Additional Proxy Materials
3

1-25 of 398

…

Recent SEC filings with analysis